Technical analyst Hemen Kapadia has maintained 'buy' rating on Bharti Airtel Limited stock with an intra-day target of Rs 1350.

According to analyst, the stock can be purchased at Rs 1334 with a stop loss of Rs 1326.

The stock of the company, on December 21, closed at Rs 1334.20 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 1349 and a low of Rs 786.85 on BSE.

Current EPS & P/E ratio stood 81.76 and 16.18 respectively.

On Dec 03, Aurobindo Pharma bagged tentative nod from the USFDA to make and sell Duloxetine Hydrochloride Delayed Release Caps in the potencies of 20mg (base), 30mg (base) and 60mg (base).

Aurobindo Pharma has recorded an increase of 92.19% in its consolidated net profit, which stood at Rs 1,983.20 million for the three month period ended September 30 as against Rs 1,031.90 million for the three month period ended September 2009.

Company's total income grew by 25.45% to Rs 11,232 million for the period under review as against Rs 8,953.40 million for the same period ended September 2009.